5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • DNA damage repair alterations as predictive biomarker for platinum-based chemotherapy in metastatic urothelial cancer
    Meeting Abstract

    Sternschuss, M.; Paynter, A.; Xu, W. X.; Nichols, C.; Hoppe, J.; Davis, N. B.; Jiang, D. M.; Shah, N. J.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Updated long-term follow-up from a phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy for patients with high-grade upper tract urothelial carcinoma
    Meeting Abstract

    Jayalath, V.; Teo, M. Y.; Assel, M.; Rodriguez, D.; Meyerson, A.; Bochner, B. H.; Dalbagni, G.; Donat, S. M.; Herr, H. W.; Cha, E. K.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Correlation of NECTIN4 amplification and expression with response to enfortumab vedotin (EV) treatment in locally advanced or metastatic urothelial carcinoma
    Meeting Abstract

    Yol, C.; Irawan, H.; Sternschuss, M.; Gupta, A.; Bent, E.; Basar, M.; Chen, J. F.; Sarungbam, J.; Chen, Y. B.; Gopalan, A.; more...
    Laboratory Investigation (2025)

    Fulltext@MSK | Save
  • Neratinib alone or in combination with immune checkpoint inhibitors with or without mammalian target of rapamycin inhibitors in patients with fibrolamellar carcinoma
    Journal Article

    Abou-Alfa, G. K.; Meyer, T.; Do, R. K. G.; Piha-Paul, S. A.; Light, J. S.; Sherrin, S.; Yaqubie, A.; O'Neill, A. C.; Harding, J. J.; Al-Rajabi, R.; more...
    Liver Cancer (2025)

    Fulltext@MSK | Save
  • Clinical and translational results from PORTER, a multicohort phase I platform trial of combination immunotherapy in metastatic castration-resistant prostate cancer
    Journal Article

    Galsky, M. D.; Autio, K. A.; Cabanski, C. R.; Wentzel, K.; Graff, J. N.; Friedlander, T. W.; Howes, T. R.; Shotts, K. M.; Densmore, J.; Spasic, M.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Genetic ancestry-based differences in biomarker-based eligibility for precision oncology therapies
    Journal Article

    Arora, K.; Suehnholz, S. P.; Zhang, H.; Ostrovnaya, I.; Kundra, R.; Nandakumar, S.; Nissan, M. H.; Brannon, A. R.; Bandlamudi, C.; Ladanyi, M.; more...
    JAMA Oncology (2025)

    Fulltext@MSK | Save
  • A study to learn how well enfortumab vedotin (EV) with pembrolizumab works and how safe it is in people with advanced urothelial cancer: A plain language summary of the EV-302/KEYNOTE-A39 study
    Editorial

    Powles, T.; Valderrama, B. P.; Gupta, S.; Bedke, J.; Kikuchi, E.; Hoffman-Censits, J.; Iyer, G.; Vulsteke, C.; Park, S. H.; Shin, S. J.; more...
    Future Oncology (2025)

    Fulltext@MSK | Save
  • Epidemiology and risk factors for testicular cancer: A systematic review
    Review

    Tateo, V.; Thompson, Z. J.; Gilbert, S. M.; Cortessis, V. K.; Daneshmand, S.; Masterson, T. A.; Feldman, D. R.; Pierorazio, P. M.; Prakash, G.; Heidenreich, A.; more...
    European Urology (2025)

    Fulltext@MSK | Save
  • Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: Final analysis of the phase III JAVELIN Renal 101 trial
    Journal Article

    Choueiri, T. K.; Penkov, K.; Uemura, H.; Campbell, M. T.; Pal, S.; Kollmannsberger, C.; Lee, J. L.; Venugopal, B.; van den Eertwegh, A. J. M.; Negrier, S.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Biomarker analyses from the phase III randomized CLEAR trial: Lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma
    Journal Article

    Motzer, R. J.; Porta, C.; Eto, M.; Hutson, T. E.; Rha, S. Y.; Merchan, J. R.; Winquist, E.; Gurney, H.; Grünwald, V.; George, S.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save